NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele
AUTOR(ES)
Tsukaguchi, Hiroyasu
FONTE
American Society for Clinical Investigation
RESUMO
Mutations in NPHS2, encoding podocin, have been identified in childhood onset focal and segmental glomerulosclerosis (FSGS). The role of NPHS2 in adult disease is less well defined. We studied 30 families with FSGS and apparent autosomal recessive inheritance and 91 individuals with primary FSGS. We screened family members for NPHS2 mutations. NPHS2 mutations appeared to be responsible for disease in nine of these families. In six families, the affected individuals were compound heterozygotes for a nonconservative R229Q amino acid substitution. This R229Q variant has an allele frequency of 3.6% in a control population. In these families, R229Q was the only mutation identified on one of the two disease-associated NPHS2 alleles. We used in vitro–translated podocin and purified nephrin to investigate the effect of R229Q on their interaction and found decreased nephrin binding to the R229Q podocin. These data suggest that this common polymorphism contributes to the development of FSGS. Chromosomes bearing the R229Q mutation share a common haplotype defining an approximately 0.2-Mb region. R229Q appears to enhance susceptibility to FSGS in association with a second mutant NPHS2 allele. Identification of R229Q mutations may be of clinical importance, as NPHS2-associated disease appears to define a subgroup of FSGS patients unresponsive to corticosteroids.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=151634Documentos Relacionados
- Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate α-secretase activity
- Late-onset peripheral joint disease in ankylosing spondylitis
- Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease
- Late-onset post-pneumonectomy empyema.
- Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease.